Baiji Shenzhou PD-1 single anti-acceptance status update, only one step away from the listing

　　Medicine Network November 14th, November 12th, Baiji Shenzhou PD-1 product for Lei Lizhu mono-resistance has ended in the CDE review process, is currently in the drug review center review queue This means that Baiji Shenzhou PD-1 for Lei LiZhu single resistance from the approved listing only one foot 　　It is understood that the Terrey Pearl single resistance will be the fourth domestic listing of local PD-1 products, but also one of the core products of Baiji Shenzhou As a result of similar products, Junsittrepri single resistance, Cinda SinDili single resistance, as well as HengrecarI Li Zhu single resistance have been listed, Baiji Shenzhou is currently slightly behind in progress But based on the extensive layout of adaptation, Baiji Shenzhou remains confident in the market in the layout of indications, Baiji Shenzhou is the first to submit urine disease of the PD-1 mono-resistance research and development , the field has not been a breakthrough treatment program for many years In addition, the company has three stage iii clinical trials of lung cancer, a non-small cell squamous cancer phase III clinical trials have been completed into the group, are in a leading position in the country In the chinese characteristics of cancer liver cancer, the treatment of 1-line hepatocellular carcinoma has entered the third phase, 2-line / 3-line treatment of single-arm clinical trial patients have been completed Wang Lai, a Baiji Shenzhou, said the company would focus its PD-1 strategy on China, which has a broad layout in terms of its characteristics For PD-1 monoantigen, Baiji Shenzhou is currently conducting 11 Phase III clinical trials, 4 Phase II registered clinical trials, and more PD-1-based combination therapies are also being explored in the market's marketing preparation, Baiji Shenzhou from 2018 began to reserve the team, the core executives are now basically in place Among them, Dr Wu Xiaobin, General Manager and President of China, was pfizer's China boss, and Chief Commercial Officer of Greater China, Wu Qingxuan, completed the successful listing of Sanofi's multiple sclerosis product, Aubagio, setting a record for the outstanding listing of Sanofi's new products, and Liu Yan, vice president and head of marketing in Greater China, helped Wutian revive Enantone's line of business and
promote the company's product line in addition, baiji Shenzhou in Guangzhou, the first phase of the large-molecule production base has been announced on October 30, 2019 The base has a total investment of 2.3 billion yuan, covers an area of 100,000 square meters, focusing on commercial scale of macromolecule biopharmaceutical technology development and production The first phase of the project took only two years to achieve a production capacity of 8000 liters, pD-1 antibody for the Reilly pearl monoantigen will be produced here at present, Baiji Shenzhou PD-1 antibody for the production and sales preparation of relizumab has been ready, product approval has entered the final queue state, everything is ready, only the east wind.